GC Wealth Management RIA LLC Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

GC Wealth Management RIA LLC boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,783 shares of the life sciences company’s stock after acquiring an additional 154 shares during the period. GC Wealth Management RIA LLC’s holdings in Illumina were worth $238,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ILMN. WCM Investment Management LLC raised its stake in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after acquiring an additional 867,673 shares during the period. ARK Investment Management LLC purchased a new stake in shares of Illumina in the fourth quarter valued at $91,714,000. Massachusetts Financial Services Co. MA raised its stake in shares of Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after acquiring an additional 631,294 shares during the period. Janus Henderson Group PLC raised its stake in shares of Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Illumina by 116.9% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock valued at $115,663,000 after acquiring an additional 466,519 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Guggenheim reduced their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Piper Sandler increased their target price on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Royal Bank of Canada reduced their target price on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, Canaccord Genuity Group cut their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $146.85.

Illumina Stock Down 1.7 %

Shares of Illumina stock opened at $84.52 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The firm’s 50-day moving average is $116.45 and its two-hundred day moving average is $130.84. The stock has a market cap of $13.39 billion, a price-to-earnings ratio of -11.01, a PEG ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.